[Clinical evaluation of anticancer therapy combined with p-aminobenzoic acid-N-xyloside].

Abstract

Paraaminobenzoic acid-N-xyloside (K-247) is a new antitumor drug, which has no direct effect on immunologic status. Clinical trial of K-247 was performed in 8 patients with for advanced or recurred gastrointestinal cancer, who had short life expectancy. Oral administration of K-247, 600 to 900 mg/day, was carried out in combination with antitumor treatments using MMC, FT-207, 5-FU, PSK or irradiation. No toxic symptoms were observed in all patients. Of the 8 patients studied, one showed an encouraging response, while the remaining 7 patients were too far advanced to respond to these treatments.

• Authors: S Fujimoto, H Ishigami, K Okui
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 9 Issue 9 Pg. 1574-9 (Sep 1982) ISSN: 0385-0684 [Print] Japan
• PMID: 6985199 (Publication Type: English Abstract, Journal Article)

Chemical References

• Aminobenzoates
• Antineoplastic Agents
• para-Aminobenzoates
• 4-aminobenzoic acid-N-xyloside
• 4-Aminobenzoic Acid

Topics

• 4-Aminobenzoic Acid (administration & dosage, adverse effects)
• Aged
• Aminobenzoates (administration & dosage)
• Antineoplastic Agents (administration & dosage, adverse effects)
• Female
• Gastrointestinal Neoplasms (drug therapy)
• Humans
• Male
• Middle Aged
• para-Aminobenzoates